HLA-G aberrant expressions have been observed in a variety of human cancers including cutaneous melanoma, mesothelioma, glioma, hematopoietic and trophoblastic tumors; lymphoproliferative disorders and carcinoma of lung, ovary, endometrium, bladder, breast, kidney, gastric and colorectal carcinoma. Here, HLA-G is linked to lymphoproliferative syndrome.